Emma Janke is a life science strategy consultant with experience in indication prioritization, technology evaluation, and opportunity assessment. She completed her Ph.D. in Neuroscience at the University of Pennsylvania where she worked on machine learning and how changes in breathing patterns are linked with animal behavior. During this time, she also served as a commercialization intern for Integral Molecular, a platform technology biotechnology company that develops monoclonal antibodies, and completed multiple pro-bono consulting projects through Penn Biotech Group. Emma also received her B.S. in Neurobiology from the University of Texas at Austin.